Business
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM –\n\n\n− Alnylam to Host TTR Investor Webinar Today at 9:30 am ET –\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system‑level approach to address persistent challenges of underdiagnosis and fragmented care in ATTR‑CM.\n\n\nATTR‑CM is a rapidly progressive, life‑threatening cause of heart failure that remains significantly underrecognized. Early and accurate diagnosis is critical to enabling access to appropriate management and improving outcomes. Despite advances in treatment, many patients remain undiagnosed for years, preventing access to necessary care. Alnylam aims to move ATTR-CM diagnosis upstream, accelerating earlier identification and enabling health systems to deliver consistent, high‑quality patient care at scale.\n\n\n“As a cardiologist, I’ve seen firsthand the devastating impact of diagnosing ATTR‑CM too late,” said Sameer Bansilal, M.D., M.S., Vice President, Global TTR Medical Lead, Alnylam Pharmaceuticals. “This is a progressive disease where timing truly matters – earlier recognition can fundamentally change a patient’s course of disease. Alnylam’s leadership in ATTR amyloidosis is grounded not only in deep science, a robust R&D program, and strong clinical evidence, but in a commitment to enduring impact – improving how this disease is identified and managed in real-world care. By working with leading health systems, technology innovators, and national clinical organizations, Alnylam is dedicated to building the infrastructure needed to diagnose ATTR-CM earlier and deliver more coordinated care.”\n\n\nStrengthening Detection and Care Coordination for ATTR-CM in Collaboration with Viz.ai\n\n\nAlnylam is partnering with Viz.ai, the leader in artificial intelligence (AI)-powered disease detection and care coordination, to develop an AI-enabled ATTR-CM care pathway designed to help cli...